Longitude Capital and Enavate Sciences led a $60m Series A funding round in OrsoBio.

Longitude Capital, a healthcare venture capital firm, and Enavate Sciences, a platform dedicated to supporting therapeutic companies advancing medicines and enabling technologies, led a $60m Series A funding round in OrsoBio, a clinical-stage biopharmaceutical company, with participation from Samsara BioCapital, NuevaBio, and Eli Lilly and Company. “We are thrilled to welcome our new investors and for the continued support from our existing investors,” Mani Subramanian, OrsoBio CEO and Founder.